Urigenital infection with Chlamydia trachomatis is a major sexually transmitted disease, a cause of infertility and one cause of pelvic inflammatory disease. Infection in the eye by the bacterium (trachoma) is also the leading worldwide cause of blindness. Chlamydia infections are treated with antibiotics, but these are effective in only about half of all cases, and even less for chronic infections. No effective vaccine against the pathogen has been developed, nor is there one on the horizon.
UCLA researchers have developed a new approach to prevent and treat infection by Chlamydia trachomatis. The scientists developed an antibody against a host protein that the pathogen uses to infect a cell. Experiments in vitro demonstrate that blocking the protein with the antibody greatly impedes infection. In vivo studies are currently being performed. The novelty of this invention lays in the identification of a host protein that is required for Chlamydia trachomatis infection. Current therapies target the pathogen itself. Thus using this antibody to block infection could lead to the first prophylaxis for Chlamydia, and possibly a new class of therapeutics as well.
|United States Of America||Issued Patent||9,624,304||04/18/2017||2005-555|
|United States Of America||Issued Patent||9,011,857||04/21/2015||2005-555|
|United States Of America||Issued Patent||8,785,602||07/22/2014||2005-555|
|United States Of America||Issued Patent||8,779,104||07/15/2014||2005-555|
|United States Of America||Issued Patent||8,648,052||02/11/2014||2005-555|
|United States Of America||Issued Patent||8,318,906||11/27/2012||2005-555|